Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis

Zheng,Zheng; Wang,Xiang; Chen,Donglei

doi:10.3892/etm.2023.11924

Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis

Authors:
- Zheng Zheng
- Xiang Wang
- Donglei Chen
View Affiliations

Affiliations: Department of Stomatology, The First People's Hospital of Nantong, Affiliated Hospital 2 of Nantong University, Nantong, Jiangsu 226000, P.R. China
Published online on: March 30, 2023 https://doi.org/10.3892/etm.2023.11924
Article Number: 224
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cis‑diamine‑dichloroplatinum II (cisplatin, CDDP) is a key chemotherapeutic regimen in the treatment of oral squamous cell carcinoma (OSCC). However, the therapeutic efficacy of cisplatin in OSCC may be hampered by chemoresistance. Therefore, the development of novel combination therapy strategies to overcome the limitations of CDDP is of great importance. The proteasome inhibitor MG132 exhibits anti‑cancer properties against various types of cancer. However, our knowledge of its anti‑cancer effects in combination with CDDP in OSCC cells remains limited. In the current study, the synergetic effects of MG132 and CDDP were evaluated in the human CAL27 OSCC cell line. CAL27 cells were treated with CDDP alone or in combination with MG132. The results showed that MG132 significantly reduced cell viability in a dose‑dependent manner. Additionally, cell viability was significantly reduced in CAL27 cells treated with 0.2 µM MG132 and 2 µM CDDP compared with cells treated with MG132 or CDDP alone. In addition, MG132 significantly enhanced the CDDP‑induced generation of intracellular reactive oxygen species and DNA damage in OSCC cells. Furthermore, treatment with CDDP or MG132 alone notably inhibited colony formation and proliferation of OSCC cells. However, co‑treatment of OSCC cells with MG132 and CDDP further hampered colony formation and proliferation compared with cells treated with either MG132 or CDDP alone. Finally, in cells co‑treated with MG132 and CDDP, the expression of p53 was markedly elevated and the p53‑mediated apoptotic pathway was further activated compared with cells treated with MG132 or CDDP alone, as shown by the enhanced cell apoptosis, Bax upregulation, and Bcl‑2 downregulation. Overall, the results of the current study support the synergistic anti‑cancer effects of a combination of MG132 and CDDP against OSCC, thus suggesting that the combination of MG132 and CDDP may be a promising therapeutic strategy for the management of OSCC.

View Figures

View References

1	Warnakulasuriya S and Kerr AR: Oral cancer screening: Past, present, and future. J Dent Res. 100:1313–1320. 2021.PubMed/NCBI View Article : Google Scholar
2	Papa F, Siciliano RA, Inchingolo F, Mazzeo MF, Scacco S and Lippolis R: Proteomics pattern associated with gingival oral squamous cell carcinoma and epulis: A case analysis. Oral Sci Int. 15:41–47. 2018.
3	Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, Arya R, Rath R, Das Majumdar SK, Muduly DK, et al: CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis. JCI Insight. 6(e143643)2021.PubMed/NCBI View Article : Google Scholar
4	Huang SH and O'Sullivan B: Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 18:e233–e240. 2013.PubMed/NCBI View Article : Google Scholar
5	Kulkarni B, Gondaliya P, Kirave P, Rawal R, Jain A, Garg R and Kalia K: Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2. Oncotarget. 11:1832–1845. 2020.PubMed/NCBI View Article : Google Scholar
6	Yuan Y, Xie X, Jiang Y, Wei Z, Wang P, Chen F, Li X, Sun C, Zhao H, Zeng X, et al: LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis. 8(e3035)2017.PubMed/NCBI View Article : Google Scholar
7	Bassermann F, Eichner R and Pagano M: The ubiquitin proteasome system-implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 1843:150–162. 2014.PubMed/NCBI View Article : Google Scholar
8	Gupta I, Singh K, Varshney NK and Khan S: Delineating crosstalk mechanisms of the ubiquitin proteasome system that regulate apoptosis. Front Cell Dev Biol. 6(11)2018.PubMed/NCBI View Article : Google Scholar
9	Bax M, McKenna J, Do-Ha D, Stevens CH, Higginbottom S, Balez R, Cabral-da-Silva MEC, Farrawell NE, Engel M, Poronnik P, et al: The ubiquitin proteasome system is a key regulator of pluripotent stem cell survival and motor neuron differentiation. Cells. 8(581)2019.PubMed/NCBI View Article : Google Scholar
10	Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr and Chen ZS: Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 48(100663)2020.PubMed/NCBI View Article : Google Scholar
11	Yang H, Chen X, Li K, Cheaito H, Yang Q, Wu G, Liu J and Dou QP: Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Semin Cancer Biol. 68:105–122. 2021.PubMed/NCBI View Article : Google Scholar
12	Guo N and Peng Z: MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 9:6–11. 2013.PubMed/NCBI View Article : Google Scholar
13	Zhu W, Liu J, Nie J, Sheng W, Cao H, Shen W, Dong A, Zhou J, Jiao Y, Zhang S and Cao J: MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo. Oncol Rep. 34:2083–2089. 2015.PubMed/NCBI View Article : Google Scholar
14	Qiang W, Sui F, Ma J, Li X, Ren X, Shao Y, Liu J, Guan H, Shi B and Hou P: Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a. Endocrine. 56:98–108. 2017.PubMed/NCBI View Article : Google Scholar
15	Guo N, Peng Z and Zhang J: Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo. Int J Gynecol Cancer. 26:839–844. 2016.PubMed/NCBI View Article : Google Scholar
16	Dang L, Wen F, Yang Y, Liu D, Wu K, Qi Y, Li X, Zhao J, Zhu D, Zhang C and Zhao S: Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells. Int J Mol Med. 33:1083–1088. 2014.PubMed/NCBI View Article : Google Scholar
17	Jiang Q, Wang Z, Qi Q, Li J, Xin Y and Qiu J: lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway. Mol Ther Oncolytics. 24:355–370. 2022.PubMed/NCBI View Article : Google Scholar
18	Lü L, Liu X, Wang C, Hu F, Wang J and Huang H: Dissociation of E-cadherin/β-catenin complex by MG132 and bortezomib enhances CDDP induced cell death in oral cancer SCC-25 cells. Toxicol In Vitro. 29:1965–1976. 2015.PubMed/NCBI View Article : Google Scholar
19	Jiang Y, Guo H, Tong T, Xie F, Qin X, Wang X, Chen W and Zhang J: lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Ther. 30:448–467. 2022.PubMed/NCBI View Article : Google Scholar
20	Huang R, Chen H, Liang J, Li Y, Yang J, Luo C, Tang Y, Ding Y, Liu X, Yuan Q, et al: Dual role of reactive oxygen species and their application in cancer therapy. J Cancer. 12:5543–5561. 2021.PubMed/NCBI View Article : Google Scholar
21	Srinivas US, Tan BWQ, Vellayappan BA and Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox Biol. 25(101084)2019.PubMed/NCBI View Article : Google Scholar
22	Aubrey BJ, Kelly GL, Janic A, Herold MJ and Strasser A: How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 25:104–113. 2018.PubMed/NCBI View Article : Google Scholar
23	Baruah A, Chang H, Hall M, Yuan J, Gordon S, Johnson E, Shtessel LL, Yee C, Hekimi S, Derry WB and Lee SS: CEP-1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants. PLoS Genet. 10(e1004097)2014.PubMed/NCBI View Article : Google Scholar
24	Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R and Lopez-Beltran A: BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett. 250:292–299. 2007.PubMed/NCBI View Article : Google Scholar
25	Han YH, Moon HJ, You BR and Park WH: The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 22:215–221. 2009.PubMed/NCBI
26	Chen SF, Chen HY, Liu XB, Zhang YX, Liu W, Wang WH, Zhang B and Wang LX: Apoptotic effect of MG-132 on human tongue squamous cell carcinoma. Biomed Pharmacother. 65:322–327. 2011.PubMed/NCBI View Article : Google Scholar
27	Tsunoda M, Fukasawa M, Nishihara A, Takada L and Asano M: JunB can enhance the transcription of IL-8 in oral squamous cell carcinoma. J Cell Physiol. 236:309–317. 2021.PubMed/NCBI View Article : Google Scholar
28	Lai WT, Li YJ, Wu SB, Yang CN, Wu TS, Wei YH and Deng YT: Connective tissue growth factor decreases mitochondrial metabolism through ubiquitin-mediated degradation of mitochondrial transcription factor A in oral squamous cell carcinoma. J Formos Med Assoc. 117:212–219. 2018.PubMed/NCBI View Article : Google Scholar
29	Luo F, Zhou Z, Cai J and Du W: DUB3 facilitates growth and inhibits apoptosis through enhancing expression of EZH2 in oral squamous cell carcinoma. Onco Targets Ther. 13:1447–1460. 2020.PubMed/NCBI View Article : Google Scholar
30	Wu J, Guo W, Wen D, Hou G, Zhou A and Wu W: Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 7:4004–4011. 2018.PubMed/NCBI View Article : Google Scholar
31	He Y, Tai S, Deng M, Fan Z, Ping F, He L, Zhang C, Huang Y and Cheng B: Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma. Cancer Med. 8:3479–3490. 2019.PubMed/NCBI View Article : Google Scholar
32	Chen H, Yang H, Pan L, Wang W, Liu X, Ren X, Liu Y, Liu W, Zhang Y, Jiang L, et al: The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress. Biomed Pharmacother. 77:108–113. 2016.PubMed/NCBI View Article : Google Scholar
33	Sung ES, Park KJ, Choi HJ, Kim CH and Kim YS: The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res. 318:1564–1576. 2012.PubMed/NCBI View Article : Google Scholar
34	Yoshiba S, Iwase M, Kurihara S, Uchida M, Kurihara Y, Watanabe H and Shintani S: Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis. Oncol Rep. 25:645–652. 2011.PubMed/NCBI View Article : Google Scholar
35	Deng D and Shah K: TRAIL of hope meeting resistance in cancer. Trends Cancer. 6:989–1001. 2020.PubMed/NCBI View Article : Google Scholar
36	Zhang Y, Yang B, Zhao J, Li X, Zhang L and Zhai Z: Proteasome inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) enhances therapeutic effect of paclitaxel on breast cancer by inhibiting nuclear factor (NF)-κB signaling. Med Sci Monit. 24:294–304. 2018.PubMed/NCBI View Article : Google Scholar
37	Kim YM and Kim HJ: Proteasome inhibitor MG132 is toxic and inhibits the proliferation of rat neural stem cells but increases BDNF expression to protect neurons. Biomolecules. 10(1507)2020.PubMed/NCBI View Article : Google Scholar
38	Kleih M, Böpple K, Dong M, Gaißler A, Heine S, Olayioye MA, Aulitzky WE and Essmann F: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 10(851)2019.PubMed/NCBI View Article : Google Scholar
39	Han YH, Kim SZ, Kim SH and Park WH: Reactive oxygen species and glutathione level changes by a proteasome inhibitor, MG132, partially affect calf pulmonary arterial endothelial cell death. Drug Chem Toxicol. 33:403–409. 2010.PubMed/NCBI View Article : Google Scholar
40	Han YH, Moon HJ, You BR and Park WH: The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner. Oncol Res. 18:315–322. 2010.PubMed/NCBI View Article : Google Scholar
41	Park S, Park JA, Yoo H, Park HB and Lee Y: Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells. Redox Biol. 13:470–476. 2017.PubMed/NCBI View Article : Google Scholar
42	Park WH and Kim SH: MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncol Rep. 27:1284–1291. 2012.PubMed/NCBI View Article : Google Scholar
43	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
44	Zhang Y, Zhang Y, Zhong C and Xiao F: Cr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes. Sci Rep. 6(34578)2016.PubMed/NCBI View Article : Google Scholar